Effect of the different phosphorylated Smad2 protein localizations on the invasive breast carcinoma phenotype

APMIS

Volumn 115, Issue 2, 2007, Pages 104-114

  Liapis, George ^a   Mylona, Eleni ^a   Alexandrou, Paraskevi ^a   Giannopoulou, Ioanna ^a   Nikolaou, Irini ^b   Markaki, Sofia ^b   Keramopoulos, Antonios ^b   Nakopoulou, Lydia ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Breast cancer; Immunohistochemistry; Invasion; Smad2; TGF

Indexed keywords

CATENIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ESTROGEN RECEPTOR; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 1; PROGESTERONE RECEPTOR; PROTEIN P120; SMAD2 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; CELL PROLIFERATION; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; STATISTICAL SIGNIFICANCE; TISSUE SECTION;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MENOPAUSE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHENOTYPE; PHOSPHORYLATION; SMAD2 PROTEIN; SURVIVAL ANALYSIS;

EID: 33846820599     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2007.apm_517.x     Document Type: Article

References (50)

1. Chin D, Boyle GM, Parsons PG, Coman WB. What is transforming growth factor-beta (TGF-β)? Br J Pl Surgery 2004;57:215-21.
2. Kretzschmar M, Massague J. SMADs: mediators and regulators of TGF-β responses. Curr Opin Genet Dev 1998;8:103-11.
3. Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science 2002;296:1646-7.
4. Wakefield LM, Piek E, Böttinger ER. TGF-β signaling in mammary gland development and tumorigenesis. J Mam Gland Biol Neo 2001;6:67-82.
5. De Cestecker MP, Piek E, Roberst AB. The role of TGF-β signaling in cancer. J Natl Cancer Inst 2000;92:1388-402.
6. Pierce DJ, Johnson MD, Matsui V, Robinson SD, Gold LJ, Purchio AF, et al. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-β1. Genes Dev 1993;7:2308-17.
7. Tang B, Bottinger EP, Jakowlew SB, Bagnall KM, Mariano J, Anver MR, et al. Transforming growth factor-b1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 1998;4:802-7.
8. Böttinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor B receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res 1997;57:5564-70.
9. Reiss M, Barcellos-Hoff MH. Transforming growth factor-β in breast cancer: a working hypothesis. Breast Cancer Res Treat 1997;45:81-95.
10. Walker RA, Dearing S. Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer 1992;28:641-4.
11. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 1992; 52:6949-52.
12. Oft M, Deli J, Rudar C, Schwartz H, Beug H, Reichman E. TGF-β1 and Ha-Ras collaborate on modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 1996;10:2462-77.
13. Weich DR, Fabra A, Nakaijama M. Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 1990;87:7678-82.
14. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103:197-206.
15. Oft M, Heider KH, Beug H. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Cell Biol 1998;8:1243-52.
16. Gobbi H, Arteaga Cl, Jensen RA, Simpson JF, Dupont WD, Olson ST, et al. Loss of expression of transforming growth factor beta type II receptor correlates with high tumor grade in human breast in situ and invasive carcinomas. Histopathology 2000;36:168-77.
17. Riggins GJ, Kinzler KW, Vogelstein B, Thiagalingam S. Frequency of Smad gene mutations in human cancer. Cancer Res 1997;57:2578-80.
18. Dumont N, Arteaga CL. Transforming growth factor-β and breast cancer: tumor promoting effects of transforming growth factor-β. Breast Cancer Res 2000;2:125-32.
19. Salo T, Lyons JG, Rahemtulla F, Birkedal-Hansen H, Larjava H. Transforming growth factor-beta 1 upregulates types IV collagenase expression in cultured human keratinocytes. J Biol Chem 1991;266:11436-41.
20. Overall CM, Wrana JL, Sodek J. Transcriptional and post-transcriptional regulation of 72 kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem 1991;266:14064-71.
21. Ravanti L, Hakkinen L, Larjava H, Saarialho-Kere U, Foschi M, Han J, et al. Transforming growth factor-β induces collagenase-3 expression by human gingival fibroblasts via p38 mitogen activated protein kinase. J Biol Chem 1999;274:37292-300.
22. Leivonen SK, Chantry A, Hakkinen L, Han J, Kahari VM. Smad3 mediates transforming growth factor-beta-induced collagenase-3 (matrix Metalloproteinase-13) expression in human gingival fibroblasts. Evidence for cross-talk between Smad3 and p38 signaling pathways. J Biol Chem 2002;277:46338-46.
23. Yuan W, Varga J. Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J Biol Chem 2001;276:38502-10.
24. Hall MC, Young DA, Waters JG, Rowan AD, Chantry A, Edwards DR, et al. The comparative role of activator protein-1 and smad factors in the regulation of TIMP-1 and MMP-1 gene expression by transforming growth factor-β1. J Biol Chem 2003;278:10304-13.
25. Xie L, Law BK, Aakre ME, Edgerton M, Shyr Y, Bhowmick NA, et al. Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line. Breast Cancer Res 2003;5:R187-98.
26. Perry I, Tselepis C, Hoyland J, Iqbal TH, Scott D, Sanders SA, et al. Reduced cadherin/ catenin complex expression in celiac disease can be reproduced in vitro by cytokine stimulation. Lab Invest 1999;79:1489-99.
27. Janji B, Melchior C, Gouon V, Vallar L, Kieffer N. Autocrine TGF-beta-regulated expression of adhesion receptors and integrin-linked kinase in HT-144 melanoma cells correlates with their metastatic phenotype. Int J Cancer 1999;83:255-62.
28. Tavassoéli FA, Devilee P. Pathology and Genetics. Tumors of the Breast and Female Genital Organs. IARC WHO Classification of Tumors, No. 4, 2003.
29. Robins P, Pinder S, de Klerk N. Histological grading of breast carcinomas: a study of interobserved agreement. Hum Pathol 1995;28:873-9.
30. Kinne DW. Staging and follow-up of breast cancer patients. Cancer 1991;67:1196-8.
31. Nakopoulou L, Lazaris AC, Kavantzas N, Alexandrou P, Athanassiadou P, Keramopoulos A, et al. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 2000;68:137-43.
32. Nakopoulou S, Katsarou S, Giannopoulou I, Alexandrou P, Tsirmpa I, Panayotopoulou E, et al. Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer. Mod Pathol 2002;15:26-34.
33. Nakopoulou L, Gakiopoulou-Givalou H, Karayiannakis AJ, Giannopoulou I, Keramopoulos A, Davaris P, et al. Abnormal a-catenin expression in invasive breast cancer correlates with poor patient survival. Histopathology 2002;40:536-46.
34. Nakopoulou L, Mylona E, Rafailidis P, Alexandrou P, Giannopoulou I, Keramopoulos A. Effects of different ERK2 protein localizations on prognosis of patients with invasive breast carcinoma. APMIS 2005;113:693-701.
35. McClelland RA, Wilson D, Leake R, Finlay P, Nicholson RI. A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. Eur J Cancer 1991;27:711-6.
36. Dumont N, Artega CL. The tumor microenvironment: a potential arbitrator of the tumor suppressive and promoting actions of TGFβ. Differentiation 2002;70:574-82.
37. Xie W, Martens JC, Reiss DJ, Rimm DL, Camp RL, Haffty BG, et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res 2002;62:497-505.
38. Hosobuchi M, Stampfer MR. Effects of transforming growth factor β on growth of human mammary epithelial cells in culture. In Vitro Cell Dev Biol 1989;25:705-13.
39. Daniel CW, Silberstein GB, Van Horn K, Strickland P, Robinson S. TGF-b1-induced inhibition of mouse mammary ductal growth: developmental specificity and characterization. Dev Biol 1989;135:20-30.
40. Dai JL, Schutte M, Bansal RK, Wilentz RE, Sugar AY, Kern SE. Transforming growth factor-β responsiveness in DPC4/SMAD4-null cancer cells. Mol Carcinog 1999;26:37-43.
41. Hynes RO, Zhao Q. The evolution of cell adhesion. J Cell Biol 2000;150:F89-F95.
42. Thoreson MA, Reynolds AB. Altered expression of the catenin p 120 in human cancer: implications for tumor progression. Differentiation 2002;70:583-9.
43. Reinholz MM, An MW, Johnsen SA, Subramaniam M, Suman VJ, Ingle JN, et al. Differential gene expression of TGFβ inducible early gene (TIEG), Smad7, Smad2 and Bard1 in normal and malignant breast tissue. Breast Cancer Res Treat 2004;166:1-14.
44. Lynch CC, Matrisian LM. Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002;70:561-73.
45. Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004;49:187-98.
46. Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 2003;194:1-11.
47. Sounni NE, Janssen M, Foidart JM, Noel A. Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol 2003;22:55-61.
48. Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger JS, Kawakatsu H, et al. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-β1. J Cell Biol 2002;157:493-507.
49. Pearson G, Robinson F, Gibson TB, Xu BE, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-83.
50. de Caestecker MP, Parks WT, Frank CJ, Castagnino P, Bottaro DP, Roberts AB, et al. Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes Dev 1998;12:1587-92.